These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 40511)

  • 21. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia.
    Gaebel W; Müller-Oerlinghausen B; Schley J
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [B-lymphocytes of the blood in schizophrenia: effect of psychotropic therapy].
    Potapova VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(9):1378-81. PubMed ID: 2866649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia.
    Lopez LV; Kane JM
    J Clin Psychiatry; 2015 Sep; 76(9):1249-50. PubMed ID: 26455671
    [No Abstract]   [Full Text] [Related]  

  • 25. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
    Chouinard G; Turnier L
    Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 28. Neuroleptic drugs and erythrocyte catechol-O-methyltransferase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Biol Psychiatry; 1982 Nov; 17(11):1339-42. PubMed ID: 6129906
    [No Abstract]   [Full Text] [Related]  

  • 29. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Practical aspects of drug resistance in schizophrenia].
    Jarema M; Kucińska M
    Psychiatr Pol; 2000; 34(5):721-40. PubMed ID: 11202015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Characteristics of the interaction of neuroleptics and antidepressants with plasma proteins (review of the literature)].
    Bender KI; Kupchikov VV; Lutsevich AN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):116-24. PubMed ID: 1686128
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma neuroleptic concentration: in search of a therapeutic window.
    Potkin S; Hahn R; Sramek J
    Clin Neuropharmacol; 1986; 9 Suppl 4():256-8. PubMed ID: 2882840
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasma level monitoring for maintenance neuroleptic therapy.
    Marder SR; Van Putten T; Aravagiri M
    Psychopharmacol Ser; 1989; 7():269-79. PubMed ID: 2574452
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical follow-up -- EEG -- serum determinations: therapeutic experience with clozapine].
    Gekiere F; Dessalles MC; Poisson N; Maitre L
    Encephale; 1996 Dec; 22 Spec No 6():16-23. PubMed ID: 9102314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.
    Horvitz-Lennon M; Mattke S; Predmore Z; Howes OD
    Am J Psychiatry; 2017 May; 174(5):421-426. PubMed ID: 28457153
    [No Abstract]   [Full Text] [Related]  

  • 37. Neuroleptic drug levels in erythrocytes and in plasma: implications for therapeutic drug monitoring.
    Garver DL
    Psychopharmacol Ser; 1989; 7():244-56. PubMed ID: 2574450
    [No Abstract]   [Full Text] [Related]  

  • 38. Radioreceptor assay of serum neuroleptic concentrations in psychiatric patients.
    Buckley M; Braithwaite R
    Br J Psychiatry; 1986 Sep; 149():384. PubMed ID: 2877706
    [No Abstract]   [Full Text] [Related]  

  • 39. Commentary: therapeutic monitoring of antipsychotic drugs.
    Curry SH
    J Clin Psychopharmacol; 1997 Apr; 17(2):124-6. PubMed ID: 10950480
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracellular lithium and clinical response.
    Casper RC; Pandey G; Gosenfeld L; Davis JM
    Lancet; 1976 Aug; 2(7982):418-9. PubMed ID: 73876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.